These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
256 related items for PubMed ID: 23727540
1. Indexing molecules for their hERG liability. Rayan A, Falah M, Raiyn J, Da'adoosh B, Kadan S, Zaid H, Goldblum A. Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540 [Abstract] [Full Text] [Related]
2. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Li Q, Jørgensen FS, Oprea T, Brunak S, Taboureau O. Mol Pharm; 2008 Jul; 5(1):117-27. PubMed ID: 18197627 [Abstract] [Full Text] [Related]
3. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets. Shen MY, Su BH, Esposito EX, Hopfinger AJ, Tseng YJ. Chem Res Toxicol; 2011 Jun 20; 24(6):934-49. PubMed ID: 21504223 [Abstract] [Full Text] [Related]
4. A binary QSAR model for classification of hERG potassium channel blockers. Thai KM, Ecker GF. Bioorg Med Chem; 2008 Apr 01; 16(7):4107-19. PubMed ID: 18243713 [Abstract] [Full Text] [Related]
5. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. Durdagi S, Duff HJ, Noskov SY. J Chem Inf Model; 2011 Feb 28; 51(2):463-74. PubMed ID: 21241063 [Abstract] [Full Text] [Related]
6. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases. Doddareddy MR, Klaasse EC, Shagufta, Ijzerman AP, Bender A. ChemMedChem; 2010 May 03; 5(5):716-29. PubMed ID: 20349498 [Abstract] [Full Text] [Related]
7. Computational investigations of hERG channel blockers: New insights and current predictive models. Villoutreix BO, Taboureau O. Adv Drug Deliv Rev; 2015 Jun 23; 86():72-82. PubMed ID: 25770776 [Abstract] [Full Text] [Related]
8. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. Ekins S, Balakin KV, Savchuk N, Ivanenkov Y. J Med Chem; 2006 Aug 24; 49(17):5059-71. PubMed ID: 16913696 [Abstract] [Full Text] [Related]
9. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel. Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML. Assay Drug Dev Technol; 2010 Dec 24; 8(6):714-26. PubMed ID: 21158686 [Abstract] [Full Text] [Related]
10. A novel structure-based virtual screening model for the hERG channel blockers. Du L, Li M, You Q, Xia L. Biochem Biophys Res Commun; 2007 Apr 20; 355(4):889-94. PubMed ID: 17331468 [Abstract] [Full Text] [Related]
14. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. Zachariae U, Giordanetto F, Leach AG. J Med Chem; 2009 Jul 23; 52(14):4266-76. PubMed ID: 19534531 [Abstract] [Full Text] [Related]
20. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Taboureau O, Jørgensen FS. Comb Chem High Throughput Screen; 2011 Jun 01; 14(5):375-87. PubMed ID: 21470179 [Abstract] [Full Text] [Related] Page: [Next] [New Search]